The list of candidates for the production of the vaccine includes Moderna, AstraZeneca, Pfizer, Johnson & Johnson, and Merck.
The list includes Moderna, AstraZeneca, Pfizer, Johnson & Johnson, and Merck & Co.
These companies will have access to additional funding, assistance in conducting clinical trials, as well as financial and logistical support, the newspaper writes.
The material of the NYT does not mention a potential vaccine from the French manufacturer Sanofi, Inovio Pharmaceuticals, and Novavax.
According to the newspaper, the decision will be announced at the White House in the coming weeks.
The administration does not comment yet.
“We cannot comment on information that affects markets,” said a spokesman for the Ministry of health and social security.
The list includes companies that are in the later stages of vaccine development and have significant production capacity.
“We have not received any information directly from the Ministry of health about whether our program is involved in operation Supersonic speed, so we can not provide additional comments,” said a Sanofi representative.
Currently, the company runs two programs, one of which, in collaboration with the British firm GlaxoSmithKline, received financial support from the office of advanced biomedical research and development (BARDA).
The United States plans to conduct large-scale clinical trials involving 100-150 thousand volunteers. The goal is to get an effective vaccine by the end of the year. To do this, it is planned to start the middle stage of testing in July.
Moderna and AstraZeneca vaccines, in collaboration with the University of Oxford, are likely to be the first to reach this stage, says Dr. Francis Collins, Director of the National Institutes of health.
The head of the National Institute for the study of allergic and infectious diseases, Dr. Anthony Fauci, on Tuesday expressed hope that by the beginning of 2021, the country will have “a couple of million doses” of the vaccine, CNN reports.